SEC filer · CIK 0000818033 · HRTX
Heron Therapeutics, Inc. /DE/
Heron Therapeutics net income: -$20.2 million for the year ending 2025-12-31. Total assets: $255.9 million at 2025-12-31.
Latest annual reportReceipt
10-K for the fiscal year ended , filed
- Net income
- -$20.2 million
- Diluted EPS
- -$0.12 per share
- Operating cash flow
- -$27.6 million
- Cash
- $28.6 million
- Total assets
- $255.9 million
- Total liabilities
- $241.5 million
As filed
Open the 10-K on SEC.govContext from the filing
For 2023–2025, Heron excludes common stock equivalents from loss per share because their effect would be anti-dilutive. The statement presents weighted-average shares in thousands and its inline facts encode scale three; these pages retain the resulting share counts. Per-share figures are exempt from that scale. Basic and diluted measures retain distinct definitions; matching denominators should not be added. Read the source filing.
Every reported measure
The latest value of each measure the company reports, as filed. Choose one for its full history, its definition and the filing behind each figure. Separate currencies and reporting intervals stay separate rows; these are reported amounts, not prices.
| Measure | Period start | Period end | Value | Filed |
|---|---|---|---|---|
| Total assets | - | 2025-12-31 | $255.9 million | 2026-02-26 |
| Total liabilities | - | 2025-12-31 | $241.5 million | 2026-02-26 |
| Stockholders equity | - | 2025-12-31 | $14.3 million | 2026-02-26 |
| Cash and cash equivalents | - | 2025-12-31 | $28.6 million | 2026-02-26 |
| Net income or loss | 2025-01-01 | 2025-12-31 | -$20.2 million | 2026-02-26 |
| Operating cash flow | 2025-01-01 | 2025-12-31 | -$27.6 million | 2026-02-26 |
| Capital expenditure payments | 2025-01-01 | 2025-12-31 | $317.0 thousand | 2026-02-26 |
| Financing cash flow | 2025-01-01 | 2025-12-31 | $14.4 million | 2026-02-26 |
| Investing cash flow | 2025-01-01 | 2025-12-31 | $16.0 million | 2026-02-26 |
| Retained earnings or deficit | - | 2025-12-31 | -$1.94 billion | 2026-02-26 |
| Basic weighted-average shares | 2025-01-01 | 2025-12-31 | 166.7 million shares | 2026-02-26 |
| Diluted weighted-average shares | 2025-01-01 | 2025-12-31 | 166.7 million shares | 2026-02-26 |
| Basic earnings per share | 2025-01-01 | 2025-12-31 | -$0.12 per share | 2026-02-26 |
| Diluted earnings per share | 2025-01-01 | 2025-12-31 | -$0.12 per share | 2026-02-26 |
| Income tax expense or benefit | 2025-01-01 | 2025-12-31 | $0 | 2026-02-26 |
| Net property, plant and equipment | - | 2025-12-31 | $12.4 million | 2026-02-26 |
| Share-based compensation expense | 2025-01-01 | 2025-12-31 | $10.3 million | 2026-02-26 |
| Operating income or loss | 2025-01-01 | 2025-12-31 | -$2.54 million | 2026-02-26 |
| Current assets | - | 2025-12-31 | $238.1 million | 2026-02-26 |
| Current liabilities | - | 2025-12-31 | $96.1 million | 2026-02-26 |
| Current accounts payable | - | 2025-12-31 | $8.99 million | 2026-02-26 |
| Net current accounts receivable | - | 2025-12-31 | $89.6 million | 2026-02-26 |
| Net inventory | - | 2025-12-31 | $92.7 million | 2026-02-26 |
| Gross profit | 2025-01-01 | 2025-12-31 | $113.6 million | 2026-02-26 |
| Research and development expense | 2025-01-01 | 2025-12-31 | $12.4 million | 2026-02-26 |
| Common shares outstanding | - | 2025-12-31 | 188.3 million shares | 2026-02-26 |
| Cash including restricted cash | - | 2025-12-31 | $28.6 million | 2026-02-26 |
| Additional paid-in capital | - | 2025-12-31 | $1.95 billion | 2026-02-26 |
| Accumulated other comprehensive income or loss | - | 2025-12-31 | $4000 | 2026-02-26 |
| Operating lease right-of-use asset | - | 2025-12-31 | $0 | 2026-02-26 |
| Operating lease liability | - | 2024-12-31 | $3.04 million | 2025-02-27 |
| Gross property, plant and equipment | - | 2025-12-31 | $25.3 million | 2026-02-26 |
| Accumulated depreciation on property, plant and equipment | - | 2025-12-31 | $12.9 million | 2026-02-26 |
| Other noncurrent assets | - | 2025-12-31 | $5.41 million | 2026-02-26 |
| Other noncurrent liabilities | - | 2025-12-31 | $4.81 million | 2026-02-26 |
| Prepaid expenses and other current assets | - | 2025-12-31 | $9.10 million | 2026-02-26 |
| Profit or loss including noncontrolling interests | 2025-01-01 | 2025-12-31 | -$20.2 million | 2026-02-26 |
| Comprehensive income or loss | 2025-01-01 | 2025-12-31 | -$20.2 million | 2026-02-26 |
| General and administrative expense | 2025-01-01 | 2025-12-31 | $54.6 million | 2026-02-26 |
| Depreciation, depletion and amortization | 2025-01-01 | 2025-12-31 | $2.31 million | 2026-02-26 |
| Nonoperating interest expense | 2025-01-01 | 2025-12-31 | $9.61 million | 2026-02-26 |
| Other nonoperating income or expense | 2025-01-01 | 2025-12-31 | $1.34 million | 2026-02-26 |
| Nonoperating income or expense | 2025-01-01 | 2025-12-31 | -$17.7 million | 2026-02-26 |
| Interest paid, net | 2025-01-01 | 2025-12-31 | $6.51 million | 2026-02-26 |
| Proceeds from issuing common stock | 2025-01-01 | 2025-12-31 | $18.3 million | 2026-02-26 |
| Operating lease payments | 2025-01-01 | 2025-12-31 | $3.20 million | 2026-02-26 |
| Change in accounts receivable | 2025-01-01 | 2025-12-31 | $10.7 million | 2026-02-26 |
| Change in inventories | 2025-01-01 | 2025-12-31 | $31.1 million | 2026-02-26 |
| Change in accounts payable | 2025-01-01 | 2025-12-31 | -$2.71 million | 2026-02-26 |
Older measures: 5 not reported in the two years before 2026-09-19
| Measure | Period start | Period end | Value | Filed |
|---|---|---|---|---|
| Interest expense | 2023-01-01 | 2023-12-31 | $3.87 million | 2024-03-12 |
| Operating expenses | 2018-01-01 | 2018-12-31 | $261.4 million | 2019-02-22 |
| Accrued current liabilities | - | 2013-12-31 | $4.70 million | 2014-03-07 |
| Pre-tax income or loss from continuing operations | 2011-01-01 | 2011-12-31 | -$11.4 million | 2012-03-26 |
| Depreciation expense | 2018-01-01 | 2018-12-31 | $1.50 million | 2019-02-22 |
Filings
- 10-Q filed 2026-08-10
- 10-Q filed 2026-05-11
- 10-K filed 2026-02-26
- 10-Q filed 2025-11-04
- 10-Q filed 2025-08-08
61 Heron Therapeutics filings with published measures: what each annual or quarterly report tagged, with the periods it covered, as reported in that filing. The histories above show the latest-filed value per period.
Inspect the source
- Entity
- HERON THERAPEUTICS, INC. /DE/ / CIK 0000818033
- Captured
- SEC response SHA-256
8fd25ff077a16f81184199b9f7eb0d0d01ac0f8ba4c3b98a3b2cdfc2ad777b2a
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
The MCP server is free and MIT-licensed: npx -y canli-mcp. If these records help your research, a star on GitHub helps other researchers find them.
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000818033.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))